Compositions and methods for treating idiopathic overactive bladder syndrome and detrusor overactivity

A technology for overactive bladder and composition, applied in the directions of biochemical equipment and methods, chemical instruments and methods, drug combinations, etc., can solve problems such as deficiencies

Pending Publication Date: 2020-01-17
ION CHANNEL INNOVATIONS
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] Despite numerous attempts to develop cures or treat diseases caused by altered smooth muscle tone, current therapies remain inadequate as they offer limited efficacy and / or significant side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and methods for treating idiopathic overactive bladder syndrome and detrusor overactivity
  • Compositions and methods for treating idiopathic overactive bladder syndrome and detrusor overactivity
  • Compositions and methods for treating idiopathic overactive bladder syndrome and detrusor overactivity

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0117] Example 1: Nonclinical Study of hMaxi-K Gene Transfer

[0118] the rat

[0119] The pathophysiology of partial urinary outlet obstruction in rat models recapitulates many relevant aspects of the corresponding lower urinary tract symptoms observed in humans. Making note of the physiological and pathophysiological similarities it is reasonable to assume that studies of the rat bladder will provide insight into at least some aspects of human bladder physiology and dysfunction.

[0120] Because the physiology of the rat bladder resembles many aspects of the human bladder, the study examined the potential utility of intravesical instillation of K channel gene therapy with hSlo cDNA (i.e., maxi-K channel) to ameliorate large cases of partial urinary outlet obstruction. Overactive bladder in a murine model.

[0121] In one study, 22 female Sprague-Dawley rats underwent partial urethral (ie outlet, PUO) obstruction and were run in parallel with 17 sham-operated control rats. ...

example 2

[0137] Example 2: Human clinical trial of hMaxi-K gene transfer

[0138] Test design

[0139] This is a Phase 1B, multicenter study evaluating the use of direct injection of Safety and potential activity of two escalating doses of hMaxi-K gene administered into the bladder wall.

[0140] The study population was otherwise healthy, infertile (eg, hysterectomy, tubal ligation, or postmenopausal (defined as last menstrual period before study entry) with overactive bladder (OAB) and detrusor overactivity. Women with cycle>12 months, or serum FSH>40mIU / L)).

[0141] Inclusion criteria included clinical symptoms of overactive bladder lasting ≥ 6 months, including at least one of the following:

[0142] 1. Frequent urination (≥8 times / 24h)

[0143] 2. Symptoms of urinary urgency (complaints of a sudden urge to urinate that are difficult to put off) or nocturia (complaints of waking up two or more times during the night to pass urine)

[0144] 3. Urge incontinence (average of 5 t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides methods of alleviating one or more signs or symptoms of smooth muscle diseases. Compositions of the disclosure may include a plasmid vector containing a nucleic acid that encodes a Maxi-K channel peptide. Compositions of the disclosure may be administered intradetrusorally to at least two or more sites at a single unit dose.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of provisional application USSN 62 / 505,382, filed May 12, 2017, the contents of which are hereby incorporated by reference in their entirety. technical field [0003] The present invention relates generally to the field of medical therapies for the amelioration of one or more symptoms associated with smooth muscle dysfunction. Specifically, the smooth muscle of the bladder is not functioning properly. [0004] Incorporation of Sequence Listings [0005] The contents of the 30 KB text file named IONC-002-001WO_SeqList.txt created on May 11, 2018 are hereby incorporated by reference in its entirety. Background technique [0006] Abnormal bladder function is a common problem that significantly affects the quality of life of millions of men and women in the United States. Many common diseases (eg, BHP, diabetes, multiple sclerosis, and stroke) alter normal bladder function. Significa...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/17A61K31/713C07K14/705A61P13/10A61K9/00A61K48/00A61K9/51
CPCA61K31/7088A61K38/177A61K48/005A61K48/0075A61P13/10C07K14/705C12N15/85C12N2830/50
Inventor 阿诺德·梅尔曼乔治·克莱斯特卡尔-埃里克·安德松
Owner ION CHANNEL INNOVATIONS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products